Chimeric Antigen Receptor Modified T Cells Infusion
Mycosis Fungoides
UNC Lineberger Comprehensive Cancer CenterCell therapyPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
29 Active assets in the Mycosis Fungoides cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Brentuximab Vedotin University of Alabama at Birmingham | Phase 3 | BB |
VITPSO Columbia University | Phase 4 | BB |
Pembrolizumab Sorrento Therapeutics, Inc. | Phase 2 | BB |
Fludarabine National Cancer Institute (NCI) | Phase 2 | BB |
MOGAMULIZUMAB Virogen Biotechnology Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Chimeric Antigen Receptor Modified T Cells Infusion is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →